- Home
- AMBC vs MLYS Comparison
AMBC vs MLYS Comparison
Compare AMBC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- MLYS
- Stock Information
- Founded
- AMBC 1971
- MLYS 2019
- Country
- AMBC United States
- MLYS United States
- Employees
- AMBC N/A
- MLYS N/A
- Industry
- AMBC Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- MLYS Health Care
- Exchange
- AMBC Nasdaq
- MLYS Nasdaq
- Market Cap
- AMBC 411.3M
- MLYS 1.0B
- IPO Year
- AMBC 1991
- MLYS 2023
- Fundamental
- Price
- AMBC $7.19
- MLYS $14.54
- Analyst Decision
- AMBC Strong Buy
- MLYS Strong Buy
- Analyst Count
- AMBC 1
- MLYS 4
- Target Price
- AMBC $15.00
- MLYS $27.00
- AVG Volume (30 Days)
- AMBC 940.8K
- MLYS 862.9K
- Earning Date
- AMBC 08-04-2025
- MLYS 08-12-2025
- Dividend Yield
- AMBC N/A
- MLYS N/A
- EPS Growth
- AMBC N/A
- MLYS N/A
- EPS
- AMBC N/A
- MLYS N/A
- Revenue
- AMBC $253,912,000.00
- MLYS N/A
- Revenue This Year
- AMBC N/A
- MLYS N/A
- Revenue Next Year
- AMBC $17.41
- MLYS N/A
- P/E Ratio
- AMBC N/A
- MLYS N/A
- Revenue Growth
- AMBC 125.08
- MLYS N/A
- 52 Week Low
- AMBC $5.99
- MLYS $8.24
- 52 Week High
- AMBC $13.64
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- AMBC 49.52
- MLYS 47.97
- Support Level
- AMBC $6.97
- MLYS $13.22
- Resistance Level
- AMBC $7.22
- MLYS $14.54
- Average True Range (ATR)
- AMBC 0.27
- MLYS 0.71
- MACD
- AMBC 0.06
- MLYS 0.00
- Stochastic Oscillator
- AMBC 90.79
- MLYS 68.37
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.